Carvedilol in cardiac hypertrophy due to use of anabolisants in rabbits

Abstract

With the intention of testing the use of carvedilol for the treatment of secondary cardiovascular alterations due to the use of AAS, an experimental study was accomplished in 30 rabbits. Heart monitoring was performed through the analysis of heart silhouette obtained from a sequence of x-rays and evaluated through the program AUTOCAD 2004^â. The use of carvedilol reduced in 13% in average the secondary myocardial hypertrophy to the use of 5 mg of nandrolone decanoate, weekly, during 9 weeks, providing remodelamento of the cardiac silhouette, with reduction of the areas, cardiac perimeters and volumes, when analyzed with the aid of the AUTOCAD 2004®. The use of carvedilol decrease in 13% the hypertrophy secondary to the chronic use of nandrolone decanoate in the dosage employed of 5mg for 9 weeks, remodeling of the cardiac silhouette. A decrease of areas, perimeters and heart size was observed when analyzed with the AUTOCAD 2004^â program. The interpretation of heart remodulation with the use of AUTOCAD 2004^® could be adopted in the veterinary medicine practice for the evaluation of the treatment of patients with long period cardiomyopathy, because its great versatility, low costs and for providing trustworthy parameters of evolution of the hipertrofic cardiomiopathy.